Yüklüyor......
Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with (177)Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for met...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4914299/ https://ncbi.nlm.nih.gov/pubmed/26871285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7245 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|